Biggest News Aggregation in the World
📰 Steven Stein News

Page 4 - Steven Stein News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Steven Stein. Real-time updates on events, politics, business and more.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...
University Hospital United States Tim Demuth Johannes Duell Steven Stein Practice Research Clinical Haematology

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023
United States University Hospital Steven Stein Tim Demuth Johannes Duell American Association For Cancer Research Annual Meeting

Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
United States University Hospital Steven Stein Johannes Duell Kaitlyn Nealy Julia Neugebauer

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

16.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix) 16.04.2023 / ...
United States University Hospital Johannes Duell Tim Demuth Steven Stein Morphosys Us Inc

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 ... | June 19, 2023
United States University Hospital Tim Demuth Steven Stein Johannes Duell Exchange Commission

Readers sound off on deregulation, benched ballers and U.S. manufacturing

Forked River, N.J.: I watched that powerful CNN town meeting from Palestine, Ohio, Wednesday night. The residents demanded answers from Alan Shaw, CEO of Norfolk Southern Railway. Shaw said he will learn from this tragedy — but he never learned from previous deaths and disasters his railroad caused. When asked directly if he would buy the homes these people have owned for years, Shaw diverted and gave lip service that offered no real answers.
United States Pearl River Kevin Oconnor Steven Goldfinger Voicer Kurt Vorndran Donald Trump

Incyte Corporation: Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents

At approval, ruxolitinib cream will be the first treatment for repigmentation in non-segmental vitiligo available in the European Union (EU) In Europe, there are approximately 1.5 million
United States Dennis Riedl Catalina Loveman Steven Stein Christine Chiou Thierry Passeron

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science